What is the projected market valuation of the Medicinal Cannabis Testing Market by 2035?

The Medicinal Cannabis Testing Market is projected to reach a valuation of 3.005 USD Billion by 2035. Read More

What was the market valuation of the Medicinal Cannabis Testing Market in 2024?

In 2024, the market valuation of the Medicinal Cannabis Testing Market was 0.6862 USD Billion. Read More

What is the expected CAGR for the Medicinal Cannabis Testing Market during the forecast period 2025 - 2035?

The expected CAGR for the Medicinal Cannabis Testing Market during the forecast period 2025 - 2035 is 14.37%. Read More

Which segment of the Medicinal Cannabis Testing Market had the highest valuation in 2024?

In 2024, the segment of Cannabinoid Profiling had the highest valuation at 0.2 USD Billion. Read More

What are the key players in the Medicinal Cannabis Testing Market?

Key players in the Medicinal Cannabis Testing Market include SC Labs, Steep Hill, Eurofins Scientific, and PharmaCann. Read More

How does the valuation of Microbial Testing compare to other testing types in 2024?

Microbial Testing had a valuation of 0.2262 USD Billion in 2024, which is higher than Pesticide Residue Testing but lower than Cannabinoid Profiling. Read More

What is the projected valuation for the Flower sample type by 2035?

The projected valuation for the Flower sample type in the Medicinal Cannabis Testing Market is expected to reach 1.2 USD Billion by 2035. Read More

Which end-use segment is anticipated to grow the most by 2035?

The Pharmaceutical Companies end-use segment is anticipated to grow the most, with a projected valuation of 1.3 USD Billion by 2035. Read More

What methodology is expected to dominate the Medicinal Cannabis Testing Market by 2035?

Chromatography is expected to dominate the Medicinal Cannabis Testing Market, with a projected valuation of 1.2 USD Billion by 2035. Read More

How does the valuation of Edibles compare to Oils in the Medicinal Cannabis Testing Market?

In 2024, Edibles had a valuation of 0.15 USD Billion, which is higher than Oils, valued at 0.0612 USD Billion. Read More

Medicinal Cannabis Testing Market

ID: MRFR/HC/41728-HCR 111 Pages Rahul Gotadki Last Updated: September 17, 2026

Medicinal Cannabis Testing Market Research Report: Size, Share, Trend Analysis By Types of Testing (Cannabinoid Profiling,contaminant Testing, Pesticide Residue Testing, Microbial Testing), By Sample Type (Flower, Concentrates, Edibles, Oils), By End Use (Research Laboratories, Pharmaceutical Companies, Agriculture), By Methodology (Chromatography, Mass Spectrometry, Immunoassay) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Medicinal Cannabis Testing Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)14.37%

2024 Market Size$ 0.69 Billion

2025 Market Size$ 0.78 Billion

2035 Market Size$ 3 Billion

Key Players

SC Labs

Steep Hill

Eurofins Scientific

PharmaCann

Cannalysis

CannaSafe

Trends

Regulatory Developments
Technological Advancements
Consumer Awareness and Demand

Opportunities

Expansion of Medicinal Cannabis Markets
Rising Consumer Awareness and Education
Regulatory Compliance and Quality Assurance

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type of Testing (USD Billion) | |
  1. 4.1.1 Cannabinoid Profiling | |
  2. 4.1.2 Contaminant Testing | |
  3. 4.1.3 Pesticide Residue Testing | |
  4. 4.1.4 Microbial Testing |
2. 4.2 Healthcare, BY Sample Type (USD Billion) | |
  1. 4.2.1 Flower | |
  2. 4.2.2 Concentrates | |
  3. 4.2.3 Edibles | |
  4. 4.2.4 Oils |
3. 4.3 Healthcare, BY End Use (USD Billion) | |
  1. 4.3.1 Research Laboratories | |
  2. 4.3.2 Pharmaceutical Companies | |
  3. 4.3.3 Agriculture |
4. 4.4 Healthcare, BY Methodology (USD Billion) | |
  1. 4.4.1 Chromatography | |
  2. 4.4.2 Mass Spectrometry | |
  3. 4.4.3 Immunoassay |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 SC Labs (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Steep Hill (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Eurofins Scientific (FR) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 PharmaCann (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Cannalysis (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 CannaSafe (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 MCR Labs (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Bureau Veritas (FR) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 CannaIQ (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE OF TESTING |
7. 6.4 US MARKET ANALYSIS BY SAMPLE TYPE |
8. 6.5 US MARKET ANALYSIS BY END USE |
9. 6.6 US MARKET ANALYSIS BY METHODOLOGY |
10. 6.7 CANADA MARKET ANALYSIS BY TYPE OF TESTING |
11. 6.8 CANADA MARKET ANALYSIS BY SAMPLE TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY END USE |
13. 6.10 CANADA MARKET ANALYSIS BY METHODOLOGY |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF TESTING |
16. 6.13 GERMANY MARKET ANALYSIS BY SAMPLE TYPE |
17. 6.14 GERMANY MARKET ANALYSIS BY END USE |
18. 6.15 GERMANY MARKET ANALYSIS BY METHODOLOGY |
19. 6.16 UK MARKET ANALYSIS BY TYPE OF TESTING |
20. 6.17 UK MARKET ANALYSIS BY SAMPLE TYPE |
21. 6.18 UK MARKET ANALYSIS BY END USE |
22. 6.19 UK MARKET ANALYSIS BY METHODOLOGY |
23. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF TESTING |
24. 6.21 FRANCE MARKET ANALYSIS BY SAMPLE TYPE |
25. 6.22 FRANCE MARKET ANALYSIS BY END USE |
26. 6.23 FRANCE MARKET ANALYSIS BY METHODOLOGY |
27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF TESTING |
28. 6.25 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE |
29. 6.26 RUSSIA MARKET ANALYSIS BY END USE |
30. 6.27 RUSSIA MARKET ANALYSIS BY METHODOLOGY |
31. 6.28 ITALY MARKET ANALYSIS BY TYPE OF TESTING |
32. 6.29 ITALY MARKET ANALYSIS BY SAMPLE TYPE |
33. 6.30 ITALY MARKET ANALYSIS BY END USE |
34. 6.31 ITALY MARKET ANALYSIS BY METHODOLOGY |
35. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF TESTING |
36. 6.33 SPAIN MARKET ANALYSIS BY SAMPLE TYPE |
37. 6.34 SPAIN MARKET ANALYSIS BY END USE |
38. 6.35 SPAIN MARKET ANALYSIS BY METHODOLOGY |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF TESTING |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USE |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY METHODOLOGY |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TYPE OF TESTING |
45. 6.42 CHINA MARKET ANALYSIS BY SAMPLE TYPE |
46. 6.43 CHINA MARKET ANALYSIS BY END USE |
47. 6.44 CHINA MARKET ANALYSIS BY METHODOLOGY |
48. 6.45 INDIA MARKET ANALYSIS BY TYPE OF TESTING |
49. 6.46 INDIA MARKET ANALYSIS BY SAMPLE TYPE |
50. 6.47 INDIA MARKET ANALYSIS BY END USE |
51. 6.48 INDIA MARKET ANALYSIS BY METHODOLOGY |
52. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF TESTING |
53. 6.50 JAPAN MARKET ANALYSIS BY SAMPLE TYPE |
54. 6.51 JAPAN MARKET ANALYSIS BY END USE |
55. 6.52 JAPAN MARKET ANALYSIS BY METHODOLOGY |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF TESTING |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USE |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY METHODOLOGY |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF TESTING |
61. 6.58 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY END USE |
63. 6.60 MALAYSIA MARKET ANALYSIS BY METHODOLOGY |
64. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF TESTING |
65. 6.62 THAILAND MARKET ANALYSIS BY SAMPLE TYPE |
66. 6.63 THAILAND MARKET ANALYSIS BY END USE |
67. 6.64 THAILAND MARKET ANALYSIS BY METHODOLOGY |
68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF TESTING |
69. 6.66 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE |
70. 6.67 INDONESIA MARKET ANALYSIS BY END USE |
71. 6.68 INDONESIA MARKET ANALYSIS BY METHODOLOGY |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF TESTING |
73. 6.70 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY END USE |
75. 6.72 REST OF APAC MARKET ANALYSIS BY METHODOLOGY |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF TESTING |
78. 6.75 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE |
79. 6.76 BRAZIL MARKET ANALYSIS BY END USE |
80. 6.77 BRAZIL MARKET ANALYSIS BY METHODOLOGY |
81. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF TESTING |
82. 6.79 MEXICO MARKET ANALYSIS BY SAMPLE TYPE |
83. 6.80 MEXICO MARKET ANALYSIS BY END USE |
84. 6.81 MEXICO MARKET ANALYSIS BY METHODOLOGY |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF TESTING |
86. 6.83 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY END USE |
88. 6.85 ARGENTINA MARKET ANALYSIS BY METHODOLOGY |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF TESTING |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY METHODOLOGY |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF TESTING |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USE |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY METHODOLOGY |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF TESTING |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USE |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY METHODOLOGY |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF TESTING |
103. 6.100 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY END USE |
105. 6.102 REST OF MEA MARKET ANALYSIS BY METHODOLOGY |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TYPE OF TESTING, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TYPE OF TESTING, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY END USE, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY METHODOLOGY, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY METHODOLOGY, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE OF TESTING, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY SAMPLE TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY METHODOLOGY, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Enquiry

Customize Report

Medicinal Cannabis Testing Market Segmentation

Medicinal Cannabis Testing Market By Type of Testing (USD Billion, 2025-2035)

Cannabinoid Profiling
Contaminant Testing
Pesticide Residue Testing
Microbial Testing

Medicinal Cannabis Testing Market By Sample Type (USD Billion, 2025-2035)

Flower
Concentrates
Edibles
Oils

Medicinal Cannabis Testing Market By End Use (USD Billion, 2025-2035)

Research Laboratories
Medicinal Cannabis Testing Market Companies
Agriculture

Medicinal Cannabis Testing Market By Methodology (USD Billion, 2025-2035)

Chromatography
Mass Spectrometry
Immunoassay

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”